Microwave tumour coagulation plusin situtreatment with cytokine-microparticles: Induction of potent anti-residual tumour immunity
- 1 May 2005
- journal article
- research article
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 21 (3) , 247-257
Abstract
After local microwave coagulation and subsequent intra-tumoural injection of microparticles encapsulating interleukin-2 and granulocyte-macrophage colony-stimulating factor, the anti-tumour efficacy against subcutaneous Lewis lung carcinoma in syngeneic mice was evaluated. This treatment elicited a potent systemic anti-tumour immunity that protected treated mice from re-challenge with the same tumour cells and caused the distal tumours in a bilateral tumour model to be rejected. Cytotoxicity assay indicated that both T- and natural killer cells acted as the effector cells in the anti-tumour immunity. These data highlight the feasibility of microwave-pre-treated in situ cancer vaccination for clinical use.Keywords
This publication has 6 references indexed in Scilit:
- Feasibility of salvage interstitial microwave thermal therapy for prostate carcinoma following failed brachytherapy: studies in a tissue equivalent phantomPhysics in Medicine & Biology, 2003
- Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidatesThe Journal of Thoracic and Cardiovascular Surgery, 2003
- Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinomaInternational Journal of Hyperthermia, 2003
- Consequences of Cell DeathJournal of Experimental Medicine, 2000
- The Induction of Tolerance by Dendritic Cells That Have Captured Apoptotic CellsJournal of Experimental Medicine, 2000
- Enhanced Tumor Protection by Granulocyte-Macrophage Colony-Stimulating Factor Expression at the Site of an Allogeneic VaccineHuman Gene Therapy, 1998